11 Lung Cancer Clinical Trials in Ann Arbor, MI (2026)

Q: How do I join a clinical trial in Ann Arbor?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you.

Recruiting Lung Cancer Studies in Ann Arbor

NCT06538636Recruiting

Prediction Augmented Screening Initiative

Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually ...

Ann Arbor, MINA23,520 participantsVA Office of Research and Development

View Study Details

NCT06424327Recruiting

A Registry for People With Lung Cancer

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery....

Ann Arbor, MI600 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06598306Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab....

Ann Arbor, MIPHASE1220 participantsAmgen

View Study Details

NCT07221474Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intism...

Ann Arbor, MIPHASE2180 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06681220Recruiting

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Parti...

Ann Arbor, MIPHASE1166 participantsVA Office of Research and Development

View Study Details

NCT07499674Recruiting

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent...

Ann Arbor, MIPHASE3132 participantsVergent Bioscience, Inc.

View Study Details

NCT05467748Recruiting

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung...

Ann Arbor, MIPHASE166 participantsVA Office of Research and Development

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Ann Arbor, MIPHASE140 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05588388Recruiting

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage...

Ann Arbor, MIPHASE239 participantsKamya Sankar

View Study Details

NCT06275360Recruiting

Repositioning Immunotherapy in VetArans With Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC....

Ann Arbor, MIPHASE225 participantsVA Office of Research and Development

View Study Details

NCT07428044Recruiting

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab d...

Ann Arbor, MIPHASE214 participantsMemorial Sloan Kettering Cancer Center

View Study Details

About Lung Cancer Clinical Trials in Ann Arbor

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 11 lung cancer clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 25,002 participants. Research is being sponsored by VA Office of Research and Development, Memorial Sloan Kettering Cancer Center, Amgen and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Ann Arbor — FAQ

Are there lung cancer clinical trials in Ann Arbor?

Yes, there are 11 lung cancer clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Ann Arbor?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.

Are clinical trials in Ann Arbor free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 11 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated August 31, 2026 from ClinicalTrials.gov